HR Execs on the Move

Vanda Pharmaceuticals

www.vandapharma.com

 
Vanda is a specialty pharmaceutical company focused on the development and commercialization of novel therapies to address high unmet medical needs and improve the lives of patients.
  • Number of Employees: 250-1000
  • Annual Revenue: $100-250 Million
  • www.vandapharma.com
  • 2200 Pennsylvania Ave NW Suite 300E
    Washington, DC USA 20037
  • Phone: 202.734.3400

Executives

Name Title Contact Details
Derek Arrison
Senior Director of Tax and Treasury Profile
Scott Howell
VP and Chief People Officer Profile

Similar Companies

Aruna Biomedical

ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.

Oragenics

Oragenics is a publicly-traded biopharmaceutical company with a pipeline of unique proprietary technologies.

UBC Heart + Lung Institute

UBC Heart + Lung Institute is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

OMICS Group Inc

OMICS Group Inc is a Henderson, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Coherus Biosciences

Coherus BioSciences is the leading biologics platform company solely focused on delivering high-quality biosimilar therapeutics that will expand patient access to life-changing medicines in regulated markets worldwide. Founded in 2010, Coherus is a late-stage biologics platform company focused on the global biosimilar market. Headquartered in the San Francisco Bay Area and composed of a team of industry veterans with decades of experience in pioneering biologics companies, our goal is to become a global leader in the biosimilar market by leveraging our team`s collective expertise in key areas such as process science, analytical characterization, protein production and clinical-regulatory development. Our commercialization partnerships include global pharmaceutical companies in Europe, Asia and Latin America. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access.